- Trial phase
- Phase 3
- Time to market
- If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
- Why 4/10
- The next hard, dated catalyst for ALK-001 is the Phase 3 NORTHSTAR topline data readout, which is not expected until H2 2029, more than 12 months away. With no near-term binary event, and TARS having an already-approved commercial product (XDEMVY) driving the majority of current value, the impact score is capped at 4.
ALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.
Price Chart
Executive Summary
ALK-001 (gildeuretinol) is a Phase 3 oral therapeutic for Stargardt disease, a rare genetic eye condition with ~36,000 U.S. patients and no approved therapy. Tarsus Pharmaceuticals (TARS) acquired it via the Alkeus Pharmaceuticals deal in August 2026 for $450M upfront plus up to $350M in milestones. Phase 2 TEASE-1 data showed a 29.5% reduction in atrophic lesion growth and 87% lower risk of significant vision loss. The pivotal Phase 3 NORTHSTAR trial is enrolling ~230 patients with topline data not expected until H2 2029. While ALK-001 has Breakthrough Therapy and Orphan Drug designations and addresses a large unmet need, the very long timeline to readout and the dilutive acquisition financing temper near-term enthusiasm. TARS already has a commercial product (XDEMVY) generating ~$174M/quarter in revenue, so ALK-001 is a pipeline expansion rather than a binary event.
How It Works
Gildeuretinol is a deuterated form of vitamin A (a modified version where some hydrogen atoms are replaced with deuterium, a heavier isotope). In Stargardt disease, a genetic defect causes toxic vitamin A dimers (called "bisretinoids") to build up in the retina, slowly destroying light-sensing cells. Gildeuretinol slows the formation of these toxic byproducts, thereby preserving retinal tissue and vision. It is taken as an oral capsule once daily.
Trial Status
The pivotal Phase 3 NORTHSTAR trial is actively enrolling approximately 230 patients with Stargardt disease. Topline data is not expected until the second half of 2029. The drug previously completed Phase 2 (TEASE-1 trial), which demonstrated a 29.5% slower annualized growth rate of atrophic lesions (p<0.001) versus an untreated control arm, and an 87% lower likelihood of experiencing significant low-light vision loss.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 NORTHSTAR trial topline data expected H2 2029 (no near-term catalyst)
- Acquisition close and integration milestones (near-term, but not a drug catalyst)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Tarsus Pharmaceuticals, Inc Press Release TARS ·Originating report